Choreo LLC Sells 13,363 Shares of Sanofi (NASDAQ:SNY)

Choreo LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 18.6% during the fourth quarter, HoldingsChannel reports. The fund owned 58,444 shares of the company’s stock after selling 13,363 shares during the quarter. Choreo LLC’s holdings in Sanofi were worth $2,819,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the 4th quarter worth approximately $25,000. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the 3rd quarter valued at $29,000. Concord Wealth Partners lifted its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Fortitude Family Office LLC lifted its position in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the period. Finally, Sunbelt Securities Inc. lifted its position in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

SNY opened at $52.87 on Friday. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. The company’s fifty day moving average price is $49.62 and its two-hundred day moving average price is $52.35. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a market cap of $134.18 billion, a price-to-earnings ratio of 21.23, a PEG ratio of 1.26 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, analysts expect that Sanofi will post 4.34 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.